Condensed Consolidated Statements of Stockholders' Equity (USD $)	Series A1Preferred Stock	Series A2 Preferred Stock	Series B Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Notes Receivable	Total
Balance, at Mar. 27, 2002
Recapitalization due to reverse merger				260	(260)
Recapitalization due to reverse merger, shares				2,600,000
Common stock issued at inception				82	737			819
Common stock issued at inception, shares				818,500
Common stock issued for technology				22	198			220
Common stock issued for technology,shares				219,658
Stock issued for cash,	25	152	175		7,415,387			7,415,739
Stock issued for cash, shares	250,000	1,517,859	1,750,002
Conversion of notes payable, including accrued interest		48	178		5,173,893			5,174,119
Conversion of notes payable, including accrued interest, shares		482,008	1,780,183
Exercise of Series A2 preferred stock warrants for cash		1			1,395			1,396
Exercise of Series A2 preferred stock warrants for cash		13,952
Exercise of options for cash				6	9,794			9,800
Exercise of options for cash,shares				63,901
Proceeds from debt allocated to preferred stock warrants and beneficial conversion feature					940,819			940,819
Stock-based compensation expense					103,112			103,112
Exercise of options for notes receivable				49	135,253		(135,302)
Exercise of options for notes receivable,shares				491,144
Net loss						(13,214,519)		(13,214,519)
Balance at Dec. 31, 2008	25	201	353	419	13,780,328	(13,214,519)	(135,302)	431,505
Balance, shares at Dec. 31, 2008	250,000	2,013,819	3,530,185	4,193,203
Stock-based compensation expense					42,776			42,776
Net loss						(755,731)		(755,731)
Balance at Dec. 31, 2009	25	201	353	419	13,823,104	(13,970,250)	(133,502)	(281,450)
Balance, shares at Dec. 31, 2009	250,000	2,013,819	3,530,185	4,193,203
Stock issued for cash,			54		1,245,954			1,246,008
Stock issued for cash, shares			541,743
Conversion of notes payable, including accrued interest			1		15,917			15,918
Conversion of notes payable, including accrued interest, shares			6,921
Exercise of Series A2 preferred stock warrants for cash		1			836			837
Exercise of Series A2 preferred stock warrants for cash		8,371
Subscription receivable					10,000			10,000
Subscription receivable,shares			4,348
Stock-based compensation expense					83,298			83,298
Net loss						(864,850)		(864,850)
Balance at Dec. 31, 2010	25	202	408	419	15,179,109	(14,835,100)	(135,302)	209,761
Balance, shares at Dec. 31, 2010	250,000	2,022,190	4,083,197	4,193,203
Stock issued for cash,				383	3,629,935			3,630,318
Stock issued for cash, shares				3,828,047
Proceeds from debt allocated to preferred stock warrants and beneficial conversion feature					296,444			296,444
Series B preferred stock issued for services			2		44,748			44,750
Series B preferred stock issued for services,shares			19,457
Stock-based compensation expense					42,378			42,378
Conversion of preferred stock to common stock in conjunction with reverse merger	(25)	(202)	(410)	1,379	(742)
Conversion of preferred stock to common stock in conjunction with reverse merger,shares	(250,000)	(2,022,190)	(4,102,654)	13,791,231
Conversion of bridge notes to common stock in conjunction with reverse merger				92	916,552			916,644
Conversion of bridge notes to common stock in conjunction with reverse merger, shares				916,644
Exchange of Q Therapeutics, Inc. common stock for Q Holdings, Inc. common stock in conjunction with reverse merger				185	(135,487)		135,302
Exchange of Q Therapeutics, Inc. common stock for Q Holdings, Inc. common stock in conjunction with reverse merger, shares				1,853,507
Net loss						(2,599,338)		(2,599,338)
Balance at Dec. 31, 2011				2,458	19,972,937	(17,434,438)		2,540,957
Balance, shares at Dec. 31, 2011				24,582,632
Stock issued for cash,				19	189,981			190,000
Stock issued for cash, shares				190,000
Stock-based compensation expense					29,308			29,308
Shares forfeited for loan default				(5)	5
Shares forfeited for loan default,shares				(50,000)
Net loss						(610,914)		(610,914)
Balance at Mar. 31, 2012				$ 2,472	$ 20,192,231	$ (18,045,352)		$ 2,149,351
Balance, shares at Mar. 31, 2012				24,722,632